Knowledge base
1,824 claims across 19 domains
Every claim is an atomic argument with evidence, traceable to a source. Browse by domain or search semantically.
All 1,824ai alignment 395health 320internet finance 306space development 227entertainment 169grand strategy 141collective intelligence 52mechanisms 34teleological economics 30living agents 30cultural dynamics 29critical systems 24energy 23teleohumanity 18living capital 10robotics 5manufacturing 5unknown 3technology 3
LLM-generated nursing care plans exhibit dual-pathway sociodemographic bias affecting both plan content and expert-rated clinical quality
A cross-sectional simulation study published in JMIR (2025) generated 9,600 nursing care plans using GPT across 96 sociodemographic identity combinations and found systematic bias operating through two distinct pathways. First, the thematic content of care plans varied by patient demographics—what t
EU Commission's December 2025 medical AI deregulation proposal removes default high-risk AI requirements shifting burden from requiring safety demonstration to allowing commercial deployment without mandated oversight
The European Commission's December 2025 proposal amends the AI Act so that AI medical devices remain within scope but are no longer subject to high-risk AI system requirements by default. The Commission retained only the power to adopt delegated or implementing acts to reinstate those requirements—n
FDA transparency requirements treat clinician ability to understand AI logic as sufficient oversight but automation bias research shows trained physicians defer to flawed AI even when they can understand its reasoning
The FDA's 2026 CDS Guidance places greater emphasis on transparency regarding data inputs, underlying logic, and how recommendations are generated. FDA explicitly noted concern about 'how HCPs interpret CDS outputs'—acknowledging automation bias exists—but treats transparency as the solution. The gu
CVD mortality stagnation after 2010 reversed a decade of Black-White life expectancy convergence because structural cardiovascular improvements drove racial health equity gains more than social interventions
Between 2000-2009, CVD mortality declined faster for Black Americans than White Americans, narrowing the Black-White life expectancy gap by 1.39 years for women and 1.44 years for men. After 2010, this convergence stopped. Counterfactual analysis shows that if pre-2010 CVD trends had continued throu
Tailored digital health interventions achieve clinically significant systolic BP reductions at 12 months in US populations experiencing health disparities, but the effect is conditional on design specificity for these populations rather than generic deployment
A systematic review and meta-analysis of 28 studies covering 8,257 patients found that digital health interventions produced clinically significant reductions in systolic blood pressure at both 6 and 12 months in populations experiencing health disparities (racial/ethnic minorities, low-income adult
Indian generic semaglutide exports enabled by evergreening rejection create a global access pathway before US patent expiry
The Delhi High Court division bench rejected Novo Nordisk's attempt to block Dr. Reddy's from exporting semaglutide, specifically citing concerns about 'evergreening and double patenting strategies.' This ruling is structurally significant because it removes the legal risk Indian manufacturers faced
Midlife CVD mortality (ages 40-64) increased in many US states after 2010 representing a reversal not merely stagnation
The distinction between stagnation and reversal is critical for understanding the severity of the post-2010 health crisis. While old-age CVD mortality (ages 65-84) continued declining but at a much slower pace, many states experienced outright increases in midlife CVD mortality (ages 40-64) during 2
Cipla's dual role as generic semaglutide entrant AND Lilly's branded tirzepatide partner exemplifies the portfolio hedge strategy for pharmaceutical companies navigating market bifurcation
Cipla, India's major generic manufacturer, is simultaneously positioned as (1) the likely dominant generic semaglutide entrant following March 2026 patent expiry and (2) Eli Lilly's exclusive distribution partner for branded tirzepatide (Yurpeak) targeting smaller Indian cities. This dual positionin
LLM clinical recommendations exhibit systematic sociodemographic bias across all model architectures because training data encodes historical healthcare inequities
A Nature Medicine study evaluated 9 LLMs (both proprietary and open-source) using 1,000 emergency department cases presented in 32 sociodemographic variations while holding all clinical details constant. Across 1.7 million model-generated outputs, systematic bias appeared universally: Black, unhouse
Regulatory rollback of clinical AI oversight in EU and US during 2025-2026 represents coordinated or parallel regulatory capture occurring simultaneously with accumulating research evidence of failure modes
The European Commission's December 2025 proposal to 'simplify' medical device regulation removed default high-risk AI system requirements from the AI Act for medical devices, while the FDA expanded enforcement discretion for clinical decision support software in January 2026. This simultaneous dereg
LLMs amplify rather than merely replicate human cognitive biases because sequential processing creates stronger anchoring effects and lack of clinical experience eliminates contextual resistance
The npj Digital Medicine 2025 paper documents that LLMs exhibit the same cognitive biases that cause human clinical errors—anchoring, framing, and confirmation bias—but with potentially greater severity. In GPT-4 studies, incorrect initial diagnoses 'consistently influenced later reasoning' until a
Value-based care requires enrollment stability as structural precondition because prevention ROI depends on multi-year attribution and semi-annual redeterminations break the investment timeline
The OBBBA introduces semi-annual eligibility redeterminations (starting October 1, 2026) that structurally undermine VBC economics. VBC prevention investments — CHW programs, chronic disease management, SDOH interventions — require 2-4 year attribution windows to capture ROI because health improveme
Multi-agent clinical AI architecture reduces computational demands 65x compared to single-agent while maintaining performance under heavy workload
Mount Sinai's peer-reviewed study distributed healthcare AI tasks (patient information retrieval, clinical data extraction, medication dose checking) among specialized agents versus a single all-purpose agent. The multi-agent architecture reduced computational demands by up to 65x while maintaining
Clinical AI errors are 76 percent omissions not commissions inverting the hallucination safety model
The NOHARM study evaluated 31 large language models against 100 real primary care consultation cases from Stanford Health Care with 12,747 expert annotations. Across all models, harms of omission accounted for 76.6% (95% CI 76.4-76.8%) of all severe errors, while commissions represented only 23.4%.
Food insecurity creates a bidirectional reinforcing loop with cardiovascular disease where disease drives dietary insufficiency through medical costs and dietary insufficiency drives disease through ultra-processed food reliance
Food insecurity and cardiovascular disease form a bidirectional reinforcing loop through two distinct mechanisms. In the CVD→food insecurity direction, medical costs drain household food budgets, forcing dietary compromises. In the food insecurity→CVD direction, budget constraints drive consumption
GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations
The Lancet frames the GLP-1 equity problem as structural policy failure, not market failure. Populations most likely to benefit from GLP-1 drugs—those with high cardiometabolic risk, high obesity prevalence (lower income, Black Americans, rural populations)—face the highest access barriers through M
after a threshold of material development relative deprivation replaces absolute deprivation as the primary driver of health outcomes
Wilkinson's epidemiological transition framework identifies a structural shift in what determines population health. Below a GDP-per-capita threshold, absolute wealth is the dominant predictor — richer societies are healthier because they can afford nutrition, sanitation, healthcare, and shelter. Ab
GLP-1 receptor agonists show 20% individual-level mortality reduction but are projected to reduce US population mortality by only 3.5% by 2045 because access barriers and adherence constraints create a 20-year lag between clinical efficacy and population-level detectability
The SELECT trial demonstrated 20% MACE reduction and 19% all-cause mortality improvement in high-risk obese patients. Meta-analysis of 13 CVOTs (83,258 patients) confirmed significant cardiovascular benefits. Real-world STEER study (10,625 patients) showed 57% greater MACE reduction with semaglutide
Clinical AI hallucination rates vary 100x by task making single regulatory thresholds operationally inadequate
Empirical testing reveals clinical AI hallucination rates span a 100x range depending on task complexity: ambient scribes (structured transcription) achieve 1.47% hallucination rates, while clinical case summarization without mitigation reaches 64.1%. GPT-4o with structured mitigation drops from 53%
No regulatory body globally has established mandatory hallucination rate benchmarks for clinical AI despite evidence base and proposed frameworks
Despite clinical AI hallucination rates ranging from 1.47% to 64.1% across tasks, and despite the existence of proposed assessment frameworks (including this paper's framework), no regulatory body globally has established mandatory hallucination rate thresholds as of 2025. FDA enforcement discretion
US heart failure mortality in 2023 exceeds its 1999 baseline after a 12-year reversal, demonstrating that improved acute ischemic care creates a larger pool of survivors with cardiometabolic disease burden
The JACC Data Report analyzing CDC WONDER database shows heart failure age-adjusted mortality rate (AAMR) followed a U-shaped trajectory: declined from 20.3 per 100,000 (1999) to 16.9 (2011), then reversed entirely to reach 21.6 in 2023—exceeding the 1999 baseline. This represents a complete structu
State clinical AI disclosure laws fill a federal regulatory gap created by FDA enforcement discretion expansion because California Colorado and Utah enacted patient notification requirements while FDA's January 2026 CDS guidance expanded enforcement discretion without adding disclosure mandates
California enacted two sequential clinical AI laws: AB 3030 (effective January 1, 2025) requires health facilities to notify patients when using generative AI to communicate clinical information and provide instructions for human contact; AB 489 (effective January 1, 2026) prohibits AI from misrepre
Hypertensive disease mortality doubled in the US from 1999 to 2023, becoming the leading contributing cause of cardiovascular death by 2022 because obesity and sedentary behavior create treatment-resistant metabolic burden
The JACC Data Report shows hypertensive disease age-adjusted mortality rate (AAMR) doubled from 15.8 per 100,000 (1999) to 31.9 (2023), making it 'the fastest rising underlying cause of cardiovascular death.' Since 2022, hypertensive disease became the leading CONTRIBUTING cardiovascular cause of de
GLP 1 cost evidence accelerates value based care adoption by proving that prevention first interventions generate net savings under capitation within 24 months
The central economic objection to value-based care transition has been that prevention doesn't pay within typical contract horizons. Providers accept upside bonuses but avoid downside risk because the financial case for investing in health (rather than treating sickness) requires a longer payback pe
Generative AI in medical devices requires categorically different regulatory frameworks than narrow AI because non-deterministic outputs, continuous model updates, and inherent hallucination are architectural properties not correctable defects
Generative AI medical devices violate the core assumptions of existing regulatory frameworks in three ways: (1) Non-determinism — the same prompt yields different outputs across sessions, breaking the 'fixed algorithm' assumption underlying FDA 510(k) clearance and EU device testing; (2) Continuous
Page 9 of 13